, Tracking Stock Market Picks
Enter Symbol:
Arqule, Inc. (ARQL) [hlAlert]

Mkt Outperform
down 68.68 %

Arqule, Inc. (ARQL) rated Mkt Outperform with price target $10 by Burrill Institutional Research

Posted on: Wednesday,  Sep 12, 2012  8:25 AM ET by Burrill Institutional Research

Burrill Institutional Research rated Mkt Outperform Arqule, Inc. (NASDAQ: ARQL) on 09/12/2012, when the stock price was $5.62.
Since then, Arqule, Inc. has lost 68.68% as of 01/22/2016's recent price of $1.76.
If you would have followed this Burrill Institutional Research's recommendation on ARQL, you would have lost 68.68% of your investment in 1227 days.

ArQule, Inc. is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company's targeted, broad-spectrum products and research programs are focused on key biological processes that are central to cancer. ArQule's lead clinical-stage products have been generated from two scientific platforms: Cancer Survival Protein modulation and Activated Checkpoint Therapy. The Cancer Survival Protein modulation platform has generated a clinical-stage product that mediates its effects by inhibiting the activity of a molecule known as c-Met, which plays multiple roles in cancer cell growth, survival, invasion, angiogenesis and metastasis. The ACT platform is designed to kill cancer cells selectively while sparing normal cells through direct activation of DNA damage response/checkpoint pathways. The Company's lead ACT program, based on the E2F-1 pathway, is partnered with Roche.

Burrill Institutional Research
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
9/12/2012 8:25 AM Buy
5.62 10.00
as of 12/31/2012
1 Week down  -0.35 %
1 Month up  4.88 %
3 Months down  -45.40 %
1 YTD down  -50.35 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy